Dallas, TX -- (SBWIRE) -- 06/22/2015 -- RnRMarketResearch.com adds "Investigation Report on China Recombinant Factor VIII Market, 2010-2019"to its store.
Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor VIII or IX, though not rare, which affects mostly males. Hemophilia A (clotting factor VIII deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor VIII while over half are in severe conditions.
Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor VIII (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor VIII too.
After entering China, recombinant factor VIII develops fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently, recombinant factor VIII in the Chinese market are all imported drugs. They mainly come from the following three companies: Baxter Bioscience Manufacturing (SW), Wyeth Farma S.A. (SP) and Bayer (the US), among which Bayer (the US) has the largest market share of 57.40% by sales value in 2014.
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=392833
As hemophiliacs' ability to pay for medical treatment keeps increasing due to economic development, the market size of recombinant factor VIII in China is expected to keep expanding.
Readers can get at least the following information from this report:
- sales status of recombinant factor VIII in China
- price of recombinant factor VIII in Chinese market
- major manufacturers of recombinant factor VIII in Chinese market
- share of dosage forms of recombinant factor VIII in China
- market outlook of recombinant factor VIII in China
The author suggests the following groups of people purchase this report:
- manufacturers of blood products
- investors/ research institutions interested in China blood products market
- any interest in the Chinese medicine market, please contact CRI for customized survey service
Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=392833
Table of Contents
1 Related Concepts of Recombinant Factor VIII
1.2 Sales Status in Global Market
2 Market Profile of Recombinant Factor VIII in China
2.1 Patent and Approval Status of Recombinant Factor VIII in China
2.2 Major Manufacturers
2.3 Market Size
3 Survey on Sales Status of Recombinant Factor VIII in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 Survey on Market Share of Major Manufacturers of Recombinant Factor VIII in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Survey on Dosage Forms of Recombinant Factor VIII in China, 2010-2014
5.1 Market Share of Different Dosage Forms by Sales Value
5.2 Market Share of Different Dosage Forms by Sales Volume
6 Reference Price of Recombinant Factor VIII in Chinese Hospitals in 2014
6.1 Baxter Bioscience Manufacturing (SW) (Trade Name: Advate)
6.2 Wyeth Farma S.A.(SP) (Trade Name: Xyntha)
7 Major Manufacturers of Recombinant Factor VIII in Chinese Market, 2010-2014
7.2 Baxter Bioscience Manufacturing
7.3 Wyeth Farma S.A.